LYN - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ACTB	actin beta	Translocation of SLC2A4 (GLUT4) to the plasma membrane Gap junction degradation Formation of annular gap junctions Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation HATs acetylate histones Prefoldin mediated transfer of substrate to CCT/TriC Folding of actin by CCT/TriC EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells Adherens junctions interactions Adherens junctions interactions Recycling pathway of L1 Recycling pathway of L1 VEGFA-VEGFR2 Pathway Interaction between L1 and Ankyrins Interaction between L1 and Ankyrins Cell-extracellular matrix interactions B-WICH complex positively regulates rRNA expression RHO GTPases activate IQGAPs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAP2K and MAPK activation UCH proteinases DNA Damage Recognition in GG-NER Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Clathrin-mediated endocytosis RHOF GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Regulation of CDH1 Function Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in pigmentation Factors involved in megakaryocyte development and platelet production Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC) Formation of the canonical BAF (cBAF) complex Formation of the polybromo-BAF (pBAF) complex Formation of the embryonic stem cell BAF (esBAF) complex Formation of the non-canonical BAF (ncBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	Quercetin Phenethyl Isothiocyanate	Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
Novel	ADAM15	ADAM metallopeptidase domain 15	Degradation of the extracellular matrix Invadopodia formation
Novel	AGXT	alanine--glyoxylate aminotransferase	Glyoxylate metabolism and glycine degradation Peroxisomal protein import Peroxisomal protein import	Pyridoxal phosphate Serine Glycine Alanine Aminooxyacetic acid N(6)-(pyridoxal phosphate)-L-lysine 4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID	Primary hyperoxaluria (HP)
Novel	AR	androgen receptor	HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Norethisterone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone propionate Oxybenzone 1-Testosterone Boldenone Calusterone Periciazine Prasterone Flufenamic acid Stanolone (R)-Bicalutamide Metribolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Dimethylcurcumin Oxymetholone Methyltestosterone Norelgestromin Stanozolol Tetrahydrogestrinone (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide BMS-564929 S-23 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide Andarine (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile LGD-2226 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norethynodrel Norgestrel Homosalate Enzacamene Luprostiol Mibolerone Phenothiazine Gestrinone Apalutamide Clascoterone Darolutamide Esculin Ligandrol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Segesterone acetate Boldenone undecylenate Echinacoside Ketodarolutamide	Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel	ARFGEF1	ARF guanine nucleotide exchange factor 1
Novel	BANK1	B cell scaffold protein with ankyrin repeats 1
Novel	BCAR1	BCAR1 scaffold protein, Cas family member	Downstream signal transduction p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
Novel	BTK	Bruton tyrosine kinase	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Potential therapeutics for SARS Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib Spebrutinib Fostamatinib Fenebrutinib Zanubrutinib Evobrutinib Tirabrutinib Abivertinib Branebrutinib Vecabrutinib	Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD) Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel	CASP3	caspase 3	Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes Apoptotic cleavage of cellular proteins SMAC, XIAP-regulated apoptotic response Apoptosis induced DNA fragmentation Degradation of the extracellular matrix Signaling by Hippo NADE modulates death signalling Stimulation of the cell death response by PAK-2p34 Caspase-mediated cleavage of cytoskeletal proteins Apoptotic cleavage of cell adhesion proteins Caspase activation via Dependence Receptors in the absence of ligand Caspase activation via Dependence Receptors in the absence of ligand Other interleukin signaling Pyroptosis CASP4-mediated substrate cleavage CASP5-mediated substrate cleavage	Pamidronic acid Acetylsalicylic acid Minocycline 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid Emricasan Incadronic acid 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide Tributyrin Oleandrin PAC-1 Glycyrrhizic acid
Novel	CASP7	caspase 7	Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes Apoptotic cleavage of cellular proteins SMAC, XIAP-regulated apoptotic response Caspase-mediated cleavage of cytoskeletal proteins	Fica Emricasan Incadronic acid
Novel	CASP9	caspase 9	Formation of apoptosome Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes NOD1/2 Signaling Pathway AKT phosphorylates targets in the cytosol Caspase activation via Dependence Receptors in the absence of ligand Constitutive Signaling by AKT1 E17K in Cancer Regulation of the apoptosome activity Regulation of the apoptosome activity	Pamidronic acid
Novel	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	CBLC	Cbl proto-oncogene C
Novel	CD19	CD19 molecule	PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Coltuximab ravtansine Blinatumomab Depatuxizumab mafodotin Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel Loncastuximab tesirine Lisocabtagene maraleucel	Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
Novel	CD22	CD22 molecule	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell CD22 mediated BCR regulation Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Epratuzumab Inotuzumab ozogamicin Moxetumomab pasudotox
Novel	CD36	CD36 molecule (CD36 blood group)	Platelet degranulation Cross-presentation of particulate exogenous antigens (phagosomes) ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Toll Like Receptor TLR6:TLR2 Cascade PPARA activates gene expression Scavenging by Class B Receptors Scavenging by Class B Receptors Transcriptional regulation of white adipocyte differentiation Intracellular metabolism of fatty acids regulates insulin secretion MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) Regulation of TLR by endogenous ligand Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
Novel	CD72	CD72 molecule	Other semaphorin interactions
Novel	CD79A	CD79a molecule	CD22 mediated BCR regulation Potential therapeutics for SARS Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers		Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel	CD79B	CD79b molecule	CD22 mediated BCR regulation Potential therapeutics for SARS Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Polatuzumab vedotin	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel	CDK1	cyclin dependent kinase 1	MAPK3 (ERK1) activation E2F-enabled inhibition of pre-replication complex formation Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Golgi Cisternae Pericentriolar Stack Reorganization APC/C:Cdc20 mediated degradation of Cyclin B Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of the APC/C Phosphorylation of Emi1 Condensation of Prophase Chromosomes MASTL Facilitates Mitotic Progression Resolution of Sister Chromatid Cohesion Condensation of Prometaphase Chromosomes Regulation of PLK1 Activity at G2/M Transition Activation of NIMA Kinases NEK9, NEK6, NEK7 Initiation of Nuclear Envelope (NE) Reformation Nuclear Pore Complex (NPC) Disassembly Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Depolymerization of the Nuclear Lamina Anchoring of the basal body to the plasma membrane MAPK6/MAPK4 signaling Ovarian tumor domain proteases TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Degradation Mitotic Prophase G1/S-Specific Transcription Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Transcriptional regulation by RUNX2 PKR-mediated signaling	Indirubin-3'-monoxime Olomoucine Hymenialdisine SU9516 Alvocidib Alsterpaullone Seliciclib AT-7519 Fostamatinib Avotaciclib

Search Results for: LYN